depending upon which multiplier you use for calculationsan early-stage biotech that has FDA approval and is entering commercial launch, the P/S ratio and EV/Revenue multiple are generally the most reliable metrics. These multiples are often used in the biotech sector during ramp up and high-growth phases, particularly when profitability has not yet materialized.
- P/S Ratio (3x-5x) and EV/Revenue (3x-5x or more) would be good starting points, as they focus on revenue and the growth potential of the company’s new commercial product.
- EV/EBITDA (8x-10x) can be useful if the company is close to breaking even or achieving positive EBITDA.
- P/E Ratio (20x-30x) may not be as relevant unless the company has begun generating consistent profits. ( Least preferred)
agree that customer in month 1 will still be refilling. i am taking conservative 4-5 refills for first yr which is factored in
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $617.6M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.0¢ | 31.5¢ | $1.783M | 5.561M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 460766 | 31.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.5¢ | 19200 | 1 |
View Market Depth
| Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
| BOT (ASX) Chart |